Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXT) was the recipient of a large decline in short interest in April. As of April 30th, there was short interest totaling 300 shares, a decline of 91.4% from the April 15th total of 3,506 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 223,293 shares, the short-interest ratio is presently 0.0 days.

Bioxytran Stock Up 2.6%

Shares of BIXT traded up $0.00 during trading hours on Monday, reaching $0.04. 27,400 shares of the company traded hands, compared to its average volume of 88,101. The company’s fifty day moving average price is $0.04 and its two-hundred day moving average price is $0.06. The company has a market capitalization of $4.04 million, a price-to-earnings ratio of -1.78 and a beta of 1.95. Bioxytran has a 12 month low of $0.03 and a 12 month high of $0.17.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.